Biopharma’s COVID Capital Comeback – A Whitepaper

What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...

Live Panel: The Unexpected IPO Boom for Biopharma in Q2

Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled “The Unexpected IPO Boom for Biopharma in Q2.” CLICK HERE TO REGISTER Q2 saw a boom in IPOs, while...

Panel Recording on 6.11: Accessing Capital in the Time of COVID

Danforth Advisors, Locust Walk, and Mintz joined on Thursday, June 11th from 2-3pm EST for the panel, “Accessing Capital in the Time of COVID: Challenges, Opportunities, and Best Practices.” During the hour, the panel discussed How COVID-19 impacted the...

Finding the invisible, how to meet Family Offices

Besides calling the Ghostbusters, how does one catch a ghost?  That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...